Clinical trial · Observational
Iron Overload in Pediatric Oncology Patients
Evaluation of Iron Overload in Pediatric Oncology and Hematopoietic Stem Cell Transplant Patients
NCT01034072CI-TRIAL-00032478completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate for iron overload in pediatric oncology and transplant patients who have completed their treatment between one to ten years ago.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Iron Overload | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Prevalence of iron overload in pediatric oncology and transplant patients post-treatment.
- timeFrame
- 1-10 years
- description
- Prevalence of iron overload in pediatric oncology and transplant patients post-treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 78 Months
- Maximum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * Patients six and a half to twenty five years of age with a history of acute myelogenous leukemia, rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, and neuroblastoma who have completed their treatment or received their last packed red blood cell transfusion at least one year prior to enrollment (which ever occurred later) and are one to ten years post-treatment. * Patients six and a half to twenty five years of age who have undergone hematopoietic stem cell transplant for any malignancy and are at least one year from their last transfusion or transplant date prior to enrollment (which ever occurred later) and are one to ten years post-transplant. * Patients who were treated at Schneider Children's Hospital or at Children's Hospital of Philadelphia. Exclusion Criteria: * Patients who have clinical evidence of chronic graft vs. host disease of skin, liver or gastrointestinal tract. * Patients with a chronic infection (viral hepatitis), liver disease (fibrosis, cirrhosis), or a history of radiation to the liver. * Patients who cannot have an MRI due to metallic implants (i.e. pacemakers, prosthetic valves, etc.) * Patients who are pregnant.
References
Publications (0)
Data not yet available
No reference posted for this study.